Freenome on Tuesday announced the launch of its new Sanderson Study, which will use its multiomics platform, in combination with real-world data, some derived from Oracle Cerner’s Learning Health Network, to improve detection and treatment of several cancers.
WHY IT MATTERSSan Francisco-based…
Source: Healthcareitnews.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
